paper_id,claim,figure_id,title,caption,local_image_path,url
PMC5854749,Figure 1 describes the step-by-step citation disposition.,PMC5854749_figure_1,Fig. 1.,Citation disposition for the literature search,./data/PMC5854749/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/3ff6c0947462/40265_2018_881_Fig1_HTML.jpg
PMC5854749,"As shown in Fig. 1, after applying the exclusion criteria, 1,127 citations remained for the abstract screening step.",PMC5854749_figure_1,Fig. 1.,Citation disposition for the literature search,./data/PMC5854749/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/3ff6c0947462/40265_2018_881_Fig1_HTML.jpg
PMC5854749,There has been a steady growth in this literature from 1993 to the present with rapid growth in 2015 and 2016 (Fig. 2).,PMC5854749_figure_2,Fig. 2.,"Growth in publications related to biosimilar switching, from 1993 to 2016",./data/PMC5854749/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/23fa4636565e/40265_2018_881_Fig2_HTML.jpg
PMC5854749,Both RCTs and RWE are available in the literature with information on switching from reference medicines to their corresponding biosimilar (Fig. 3).,PMC5854749_figure_3,Fig. 3.,"Types of study designs across larger and smaller biologics. Biosimilars of adalimumab, etanercept, and rituximab were approved as of the cut-off date for manuscript. However, there was likely insufficient time for completion and publication of RWE with etanercept and rituximab, and a biosimilar adalimumab was not marketed as of the cut-off date. RCT randomized clinical trial, RWE real world evidence, rHuEPO recombinant human erythropoietin, GH growth hormone",./data/PMC5854749/images/figure_3.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/f72234c253b0/40265_2018_881_Fig3_HTML.jpg
PMC5854749,"In support of their biosimilar filgrastim registration, the sponsor conducted a clinical safety and efficacy study that incorporated five switchover events (Fig. 4), comparing 107 breast cancer patients that had been switched with 51 patients that had been treated continuously with either the reference medicine or the biosimilar [28].",PMC5854749_figure_4,Fig. 4.,"Switching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropenia",./data/PMC5854749/images/figure_4.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/0e828c87b8d0/40265_2018_881_Fig4_HTML.jpg
PMC5854749,"Open in a new tab
Switching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropeniaA cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",PMC5854749_figure_5,Fig. 5.,Switching study design for biosimilar etanercept (GP2015) versus reference medicine. wk week,./data/PMC5854749/images/figure_5.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/71f8f861ab2d/40265_2018_881_Fig5_HTML.jpg
PMC5854749,"A cross-over study design incorporating three switchover events (Fig. 5) was incorporated into the clinical safety and efficacy study that supported licensure of a biosimilar etanercept, GP2015 [24].",PMC5854749_figure_5,Fig. 5.,Switching study design for biosimilar etanercept (GP2015) versus reference medicine. wk week,./data/PMC5854749/images/figure_5.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f39/5854749/71f8f861ab2d/40265_2018_881_Fig5_HTML.jpg
